Ryo Amagai

445 total citations
47 papers, 278 citations indexed

About

Ryo Amagai is a scholar working on Oncology, Immunology and Dermatology. According to data from OpenAlex, Ryo Amagai has authored 47 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 22 papers in Immunology and 20 papers in Dermatology. Recurrent topics in Ryo Amagai's work include Cutaneous lymphoproliferative disorders research (18 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Ryo Amagai is often cited by papers focused on Cutaneous lymphoproliferative disorders research (18 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (12 papers). Ryo Amagai collaborates with scholars based in Japan. Ryo Amagai's co-authors include Taku Fujimura, Yumi Kambayashi, Setsuya Aiba, Akira Hashimoto, Yoshihide Asano, Hideo Harigae, Kyohei Nakamura, Yusuke Muto, M. NAKAYAMA and Mitsuko Kawano and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Ryo Amagai

44 papers receiving 277 citations

Peers

Ryo Amagai

ONCOL

IMMUN

DERMA

PFM

Derek V. Chan United States

Allison Hanlon United States

Frank Friedrich Gellrich Germany

P.A. Usher Denmark

Felix Weihsengruber Austria

Hiroaki Kamijo Japan

Isabel Meininger Germany

Shuntaro Oniki Japan

Edgar Fernández-Malavé Spain

Sarah Renaudineau France

Derek V. Chan United States

Ryo Amagai

99 ×0.7

ONCOL

153 ×1.1

IMMUN

99 ×1.3

30 ×0.4

DERMA

29 ×0.9

PFM

Citations per year, relative to Ryo Amagai Ryo Amagai (= 1×) peers Derek V. Chan

Countries citing papers authored by Ryo Amagai

Since Specialization

Citations

This map shows the geographic impact of Ryo Amagai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryo Amagai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryo Amagai more than expected).

Fields of papers citing papers by Ryo Amagai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryo Amagai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryo Amagai. The network helps show where Ryo Amagai may publish in the future.

Co-authorship network of co-authors of Ryo Amagai

This figure shows the co-authorship network connecting the top 25 collaborators of Ryo Amagai. A scholar is included among the top collaborators of Ryo Amagai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryo Amagai. Ryo Amagai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamazaki, Emi, et al.. (2025). Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene. Cancers. 17(2). 324–324. 2 indexed citations

Amagai, Ryo, Taku Fujimura, Yumi Kambayashi, et al.. (2024). The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study. Journal of Clinical Medicine. 13(18). 5560–5560. 4 indexed citations

Muto, Yusuke, Yumi Kambayashi, Hiroshi Kato, et al.. (2024). Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Cancers. 16(15). 2755–2755. 3 indexed citations

Amagai, Ryo, Toshiya Takahashi, H. Terui, et al.. (2023). The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. International Journal of Molecular Sciences. 24(1). 875–875. 11 indexed citations

Muto, Yusuke, Yumi Kambayashi, Hiroshi Kato, et al.. (2023). Adverse events associated with postoperative outcomes of adjuvant anti‐PD‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. The Journal of Dermatology. 51(3). 458–462. 1 indexed citations

Amagai, Ryo, et al.. (2023). LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages. Cancers. 15(6). 1678–1678. 7 indexed citations

Amagai, Ryo, et al.. (2023). CD25 Expression Could Be a Prognostic Marker of Bexarotene Monotherapy for Cutaneous T-Cell Lymphomas. SHILAP Revista de lepidopterología. 3(3). e222–e222. 2 indexed citations

Fujimura, Taku, Koji Yoshino, Hiroshi Kato, et al.. (2023). Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol. Experimental Dermatology. 33(1). e14976–e14976. 7 indexed citations

Amagai, Ryo, Taku Fujimura, Yumi Kambayashi, et al.. (2023). Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab. SHILAP Revista de lepidopterología. 16(1). 1490–1493. 1 indexed citations

10.

Amagai, Ryo, et al.. (2022). 326 An antimicrobial peptide LL37 facilitates immunological functions via multiple cell surface receptors. Journal of Investigative Dermatology. 142(12). S236–S236. 1 indexed citations

11.

Amagai, Ryo, et al.. (2022). Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases. SHILAP Revista de lepidopterología. 15(3). 1114–1120. 1 indexed citations

12.

Muto, Yusuke, Yumi Kambayashi, Hiroshi Kato, et al.. (2022). Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. Acta Dermato Venereologica. 102. adv00756–adv00756. 10 indexed citations

13.

Kimura, Yutaka, et al.. (2021). Optimization of the IL-2 Luc assay for immunosuppressive drugs: a novel in vitro immunotoxicity test with high sensitivity and predictivity. Archives of Toxicology. 95(8). 2755–2768. 6 indexed citations

14.

Fujimura, Taku, Yota Sato, Kayo Tanita, et al.. (2020). Case series of cutaneous T‐cell lymphomas treated with bexarotene‐based therapy. The Journal of Dermatology. 47(6). 636–640. 5 indexed citations

15.

Muto, Yusuke, Taku Fujimura, Yumi Kambayashi, et al.. (2020). Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy. Dermatologic Therapy. 33(6). e14430–e14430.

16.

Fujimura, Taku, Ryo Amagai, Yota Sato, et al.. (2020). Increased expression of dermal LL37 may trigger migration of CCR7+ regulatory T cells in extramammary Paget’s disease. Journal of Dermatological Science. 99(1). 65–68. 4 indexed citations

17.

Muto, Yusuke, Taku Fujimura, Yumi Kambayashi, et al.. (2020). Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock. Case Reports in Oncology. 13(3). 1141–1144. 3 indexed citations

18.

Fujimura, Taku, et al.. (2019). Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy. Case Reports in Oncology. 12(3). 829–833. 5 indexed citations

19.

Fujimura, Taku, Yota Sato, Kayo Tanita, et al.. (2019). Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma. Frontiers in Medicine. 6. 86–86. 15 indexed citations

20.

Amagai, Ryo, Taku Fujimura, Yumi Kambayashi, et al.. (2018). Keratoacanthoma Centrifugum Marginatum with Spontaneous Regression and Its Possible Differential Diagnosis. Case Reports in Oncology. 11(3). 671–675. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact